Epizyme (NASDAQ:EPZM) Sees Large Volume Increase

Shares of Epizyme Inc (NASDAQ:EPZM) saw an uptick in trading volume on Monday . 92,049 shares changed hands during trading, a decline of 86% from the previous session’s volume of 680,323 shares.The stock last traded at $18.88 and had previously closed at $18.22.

A number of analysts have commented on the company. ValuEngine cut Epizyme from a “hold” rating to a “sell” rating in a research report on Thursday, November 7th. Cowen reiterated a “buy” rating and issued a $18.00 price target on shares of Epizyme in a research report on Thursday, October 31st. Morgan Stanley upgraded Epizyme from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $12.00 to $22.00 in a research note on Thursday. Zacks Investment Research downgraded Epizyme from a “hold” rating to a “sell” rating and set a $11.00 price objective on the stock. in a research report on Monday, October 21st. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Epizyme in a research note on Thursday, October 31st. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. Epizyme has a consensus rating of “Buy” and an average price target of $18.14.

The company has a quick ratio of 10.90, a current ratio of 10.90 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $1.66 billion, a PE ratio of -11.20 and a beta of 2.58. The company’s 50 day moving average is $14.00 and its two-hundred day moving average is $12.90.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.11. Epizyme had a negative net margin of 468.53% and a negative return on equity of 49.38%. The business had revenue of $5.72 million for the quarter, compared to analysts’ expectations of $5.50 million. Analysts forecast that Epizyme Inc will post -1.89 EPS for the current year.

Large investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Epizyme by 29.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,564 shares of the biopharmaceutical company’s stock worth $57,000 after acquiring an additional 1,262 shares in the last quarter. TD Asset Management Inc. raised its position in Epizyme by 7.0% in the 2nd quarter. TD Asset Management Inc. now owns 21,394 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 1,400 shares during the period. California State Teachers Retirement System raised its position in Epizyme by 1.6% in the 3rd quarter. California State Teachers Retirement System now owns 121,524 shares of the biopharmaceutical company’s stock worth $1,254,000 after purchasing an additional 1,962 shares during the period. Swiss National Bank lifted its stake in Epizyme by 1.8% in the second quarter. Swiss National Bank now owns 132,700 shares of the biopharmaceutical company’s stock worth $1,665,000 after purchasing an additional 2,400 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY boosted its position in shares of Epizyme by 18.3% during the first quarter. Metropolitan Life Insurance Co NY now owns 19,570 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 3,029 shares during the period. Institutional investors own 86.92% of the company’s stock.

About Epizyme (NASDAQ:EPZM)

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Featured Article: How do candlesticks reflect price movement?

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.